Apollo Hospitals Enterprise (APOLLOHOSP) Weekly Analysis
Price & Volume
The stock price rose by 2.5% during the week, marking a positive trend. This upward movement occurred alongside a 2.43% price range, indicating moderate fluctuations in daily trading. The stock closed at 7699.0, maintaining a level above both its 50-day and 200-day moving averages.
Technicals
The market shows a positive trend this week, with the price closing at 7699.0. Moving Averages (MAs), which smooth out price fluctuations to show the average direction, are both sloping upward, indicating a consistent trend. Momentum, measured by the Relative Strength Index (RSI) and MACD, shows increased strength. The RSI, which tracks the speed of price changes, rose to 59.31. The MACD, a tool that identifies changes in momentum, shows the main line above the signal line. Volatility, or the range of price movement, remains stable with Bollinger Band width at 7.12%.
Fundamentals
Apollo Hospitals Enterprise demonstrates consistent growth, with revenue reaching ₹21,794 in Mar 2025, reflecting a 3-year compound annual growth rate (CAGR)—the average annual growth rate over three years—of 14.1%. Profitability has strengthened, as net profit rose 61.0% YoY—year-over-year, comparing the current period to the same period last year—to ₹1,505 in Mar 2025. The company maintains a solid return on equity (ROE)—a measure of profitability relative to shareholder investment—at 19.9%. Furthermore, operating profit reached ₹3,033 in Mar 2025, while the TTM—trailing twelve months, a snapshot of the last year—EBITDA margin—a measure of operational efficiency before interest, taxes, and depreciation—stands at 15.5%. These figures highlight a sustained expansion in both scale and operational performance.
News
During the week of April 13, 2026, to April 19, 2026, Apollo Hospitals Enterprise Ltd. experienced notable shifts in market sentiment and technical positioning. On April 13, the stock formed a golden cross, and by April 14, it received an upgrade to a buy rating supported by strong fundamentals. Technical momentum continued to shift toward a bullish outlook by April 15, reflecting sustained long-term returns. Furthermore, data released on April 17 indicated that institutional investors increased their stakes in the company during the fourth quarter of the 2026 fiscal year. These developments collectively highlighted a period of positive institutional engagement and strengthening technical indicators for the firm throughout the reported timeframe.
Events
Apollo Hospitals Enterprise Limited has acquired an additional 775,744 equity shares of Apollo Health and Lifestyle Limited (AHLL) for ₹18.69 crore, resulting in the company achieving 100% ownership of the subsidiary.
Apollo Hospitals Enterprise Limited has received the NCLT order dated March 26, 2026, regarding its proposed composite scheme of arrangement involving Apollo Healthco, Keimed Private Limited, and Apollo Healthtech. The tribunal has provided directions for convening meetings of shareholders and creditors to consider the scheme.
Apollo Hospitals Enterprise Limited has confirmed compliance with Regulation 74(5) of SEBI regulations for the quarter ended 31st March 2026, verifying the dematerialization of securities and the updating of depository records.
The National Company Law Tribunal has approved the application for a composite scheme of arrangement involving Apollo Hospitals Enterprise Limited and its affiliates. The order directs the company to convene meetings of shareholders and creditors to seek their approval for the proposed restructuring.
Apollo Hospitals Enterprise Limited has received board approval to establish a new multi-speciality hospital in Dwarka, New Delhi, on a 9.33-acre land parcel leased from the Delhi Development Authority. The project will be executed through a special purpose vehicle with an annual license fee of ₹33.3 crore starting from the fifth year.
Apollo Hospitals Enterprise Limited has received the NCLT order dated March 26, 2026, regarding its proposed composite scheme of arrangement involving Apollo Healthco, Keimed Private Limited, and Apollo Healthtech. The tribunal has provided directions for convening meetings of shareholders and creditors to consider the scheme.
Apollo Hospitals Enterprise Limited has confirmed compliance with Regulation 74(5) of SEBI regulations for the quarter ended 31st March 2026, verifying the dematerialization of securities and the updating of depository records.
The National Company Law Tribunal has approved the application for a composite scheme of arrangement involving Apollo Hospitals Enterprise Limited and its affiliates. The order directs the company to convene meetings of shareholders and creditors to seek their approval for the proposed restructuring.
Apollo Hospitals Enterprise Limited has received board approval to establish a new multi-speciality hospital in Dwarka, New Delhi, on a 9.33-acre land parcel leased from the Delhi Development Authority. The project will be executed through a special purpose vehicle with an annual license fee of ₹33.3 crore starting from the fifth year.
Weekly Snapshot
Highlights
- The stock price increased by 2.5% this week, maintaining a position above its 50-day and 200-day moving averages.
- Technical momentum strengthened as the Relative Strength Index (RSI, which tracks the speed of price changes) rose to 59.31.
- Apollo Hospitals achieved full ownership of Apollo Health and Lifestyle Limited after acquiring the remaining shares for Rs 18.69 crore.
- The company received board approval to develop a new multi-speciality hospital in Dwarka, New Delhi, on a 9.33-acre land parcel.
- Institutional investors increased their holdings in the company during the fourth quarter of the 2026 fiscal year.
What This Means
Apollo Hospitals experienced a positive week characterized by both financial growth and strategic expansion. The stock price rose by 2.5%, supported by technical indicators like the MACD (a tool that identifies changes in momentum) showing a positive trend. The company solidified its business structure by reaching 100% ownership of its subsidiary, Apollo Health and Lifestyle Limited, and secured approval for a new hospital project in Dwarka. Market sentiment remained favorable, with institutional investors increasing their stakes and analysts noting strong fundamentals.
Latest Quarter Info
For the quarter ending December 2025, the company demonstrated solid financial momentum, characterized by a 17.19% year-over-year revenue growth and a 36.15% surge in net profit. On a sequential basis, revenue grew by 2.74%, while net profit saw a 4.45% increase, signaling consistent operational progress. The business maintained an operating margin of 15%, reflecting stable cost management relative to its top-line performance. Despite the impact of interest and depreciation expenses, the company achieved a profit before tax of 682.0, ultimately resulting in a net profit of 516.0. The earnings per share growth of 34.92% year-over-year highlights enhanced profitability for shareholders, supported by a tax rate of 24%. Overall, the quarterly results indicate a healthy balance between revenue expansion and margin preservation, with positive trends observed across both quarterly and annual comparisons.